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doi:10.1016/j.jtcvs.2007.12.0861142 The Journal of Thoracic and CardObjective: A stented bovine pericardial valve might be less obstructive than a stented
porcine valve. This study compared early hemodynamic function in a prospective se-
ries of 99 patients randomized to receive either a Mosaic or Perimount replacement
aortic valve.
Methods: Echocardiography was performed early after surgery and at 1 year after sur-
gery. Patients also filled in psychologic questionnaires and underwent a 6-minute
walk.
Results: The groups were matched demographically. The Perimount valve was signif-
icantly less obstructive in terms of mean pressure difference (11 6 5 vs 17 6 7 mm
Hg; P, .0001), with a trend in favor of a larger effective orifice area (1.476 0.45 vs
1.286 0.46 cm2; P5 .05) postoperatively. There were no differences in left ventric-
ular mass regression, aortic regurgitation, 6-minute walk, psychologic questionnaires,
or mortality and clinical events.
Conclusion: The stented bovine pericardial valve was less obstructive than the stented
porcine valve. Both valves were associated with similar and significant improvements
in quality of life, exercise ability, and regression of left ventricular mass.
T
here is a perception that stented pericardial valves have better hemodynamic
function than stented porcine valves.1-3 However, comparing studies is diffi-
cult because of differences in echocardiographic methods and the frequent re-
liance on flow-dependent measures of prosthetic valve function. Sizing conventions
also differ between valve types so that it may not be appropriate to compare valves
of the same label size.4 There are few randomized comparisons, and these give con-
tradictory results, with a pericardial design either superior5 or similar6 to a porcine
valve.
We therefore designed a randomized trial to compare hemodynamic function in the
Medtronic Mosaic porcine valve (Medtronic, Inc, St Paul, Minn) and the Carpentier-
Edwards Perimount bovine pericardial valve (Edwards Lifesciences, Irvine, Calif).
Secondary end points were clinical event rates, exercise capacity, and measures of
overall health in the first year after surgery.
Methods
Patients
A total of 100 consecutive patients scheduled to have single bioprosthetic valve replacement in
the aortic position were randomized. All subjects were aged 19 to 90 years and none was un-
dergoing redo valve surgery or had a preoperative creatinine value of more than 500 mmol/L
or a coexistent illness known to have a significant mortality. After randomization, 1 patient re-
ceived a mechanical valve because of an aberrant origin of both coronary arteries, which left
a population of 99. Of these, because of procedural difficulties, 2 patients randomized to receive
a Perimount valve received aMosaic valve and 1 randomized to receive aMosaic valve receivediovascular Surgery c November 2008
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LV 5 left ventricular
NS 5 no significant difference
NYHA 5 New York Heart Association
SD 5 standard deviation
SF-36 5 Short Form-36 health questionnaire
a Perimount instead. The study population comprised 51 with a Mo-
saic and 48 with a Perimount valve. The mean age was 75.5 years
(range 58–89 years) and 61 (60%) were male (Table 1). The study
was accepted by the local committee on ethical practice and all pa-
tients gave written informed consent.
Surgery
Both valves were implanted according to their manufacturer’s rec-
ommendations, giving a supra-annular position for the Mosaic and
a partially supra-annular position for the Perimount valves. The
number on the sizers of the Mosaic bioprosthesis denotes the size
of the valve to be used in the supra-annular position, so that the label
size is expected to be larger than the annulus diameter. By contrast,
TABLE 1. Demographic data
Mosaic Perimount
N 51 48
Age (y) 77 (61–89) 75 (58–88)
Male/female 30:21 31:17
Etiology
AS 45 44
AR 3 2
Mixed AVD 3 2
Previous cardiac
procedures
0 2 (1 CABG, 1 PPM)
Effective orifice area
(cm2)
0.83 6 0.51 0.75 6 0.41
Mean pressure drop
(mm Hg)
47 6 20 43 6 18
Concomitant
procedures
26 CABG 23 CABG, 1 aortic root
replacement
Preop NYHA
I 7 2
II 24 20
III 20 24
IV 0 2
Height (cm) 167 6 9 166 6 8
Weight (kg) 74 6 13 74 614
BSA (m2) 1.82 6 0.19 1.82 6 0.19
BMI 26.8 6 3.8 26.5 6 4.5
EuroSCORE 8 6 5 8 6 4
Parsonnet 20 6 8 21 6 8
AS, Aortic stenosis; AR, aortic regurgitation; AVD, aortic valve disease;
CABG, coronary artery bypass grafting; PPM, permanent pacemaker;
NYHA, New York Heart Association; BSA, body surface area; BMI, body
mass index.The Journal of Thorathe number on the sizer of the Perimount bioprosthesis denotes the
size of the valve to be used in the intra-annular position. A universal
sizer (graduated in millimeters) was therefore used to determine the
actual diameter of the patient tissue annulus and then both the Peri-
mount and Mosaic sizers were used before the randomization enve-
lope was opened. The surgeon implanted the valve by his routine
technique using noneverting, vertical mattress sutures (n 5 78) or
continuous sutures (n 5 21).
Echocardiography
The majority of studies were performed by one sonographer
(H.M.R.) immediately postoperatively and at 1 year (10–14 months)
using a Vivid-7 system (GEMedical, Milwaukee, Wis). All patients
had a postoperative study, but 22 did not have a study at 1 year (11
dead, 3 agreed to telephone follow-up only, 1 declined all follow-up,
5 were unable to travel because of illness, and 2 were completely lost
to follow-up). Measurements were made as recommended by the
American Society of Echocardiography7 over 3 cycles in sinus
rhythm or over 6 cycles in atrial fibrillation. Regurgitant jets were
localized, then graded by a combination of the diameter of the
base of the jet, and the density and slope of the aortic regurgitant sig-
nal recorded by continuous wave Doppler sonography. Mild regur-
gitation was defined by a jet height less than 25% of the outflow
diameter and a complete, low-intensity continuous waveform with
pressure half-time longer than 500 ms. Trivial regurgitation was de-
fined by a thin low-momentum jet ending close to the valve with an
incomplete continuous waveform. No jet in this study was found to
be moderate or severe.
Calculations
The following calculations were performed: effective orifice area by
the continuity equation (EOA in cm2)5 CSA3 VTI1/VTI2, where
CSA is left ventricular (LV) outflow cross-sectional area (cm2) cal-
culated from the diameter assuming circular cross section, VTI1 is
subaortic velocity integral (cm), and VTI2 is aortic velocity integral
(cm); peak pressure difference across the aortic valve (peak DP in
mm Hg)5 4 (v2
22 v1
2) where v2 is transaortic peak velocity (m/s)
and v1 is subaortic peak velocity (m/s); mean pressure difference
across the aortic valve (mean DP in mm Hg) 5 aortic mean DP 2
subaortic mean DP; LV mass (gm) 5 0.83 (LVDD 1 IVS 1
PW)32 (LVDD)3, where LVDD is left ventricular diastolic diame-
ter, IVS is interventricular septal width, and Posterior Wall width
(PW) is .. Effective orifice area and LV mass were indexed to
body surface area. Patient–prosthesis mismatch was defined by an
indexed effective orifice area (EOAi) , 0.85 cm2/m2 and severe
mismatch by EOAi , 0.65 cm2/m2.
Clinical Events
Patients were interviewed at 3 to 6 months and at 1 year. The defi-
nitions used were as recommended by the guidelines of The Society
of Thoracic Surgeons and the American Association for Thoracic
Surgery.8 If the exact timing of an event was not known, it was taken
as perioperative if noted at the immediate postoperative visit. It was
recorded as at the midpoint between two visits if absent at the first
and present at the second. Early events occurred in the first 30
days and late events between 30 days and 12 months. Dysarrhyth-
mic deaths after recovery from the anesthetic but before discharge
were included as valve-related. Dysarrhythmias after surgery werecic and Cardiovascular Surgery c Volume 136, Number 5 1143
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Late events were collected by telephone at 6 months and by ques-
tionnaire at the time of the 12-month echocardiogram
Functional Assessment
The Short Form-36 (SF-36) health questionnaire9,10 and the Hospi-
tal Anxiety and Depression scale11 were given preoperatively
(within 6 weeks assuming no new clinical event) and at 1 year (10
and 14 months). The mental composite score and physical compos-
ite score of the SF-36 questionnaire were calculated.9 New York
Heart Association (NYHA) class was recorded. In addition, the 6-
minute walk was recorded before surgery and at 1 year. This test
has been validated for patients with heart failure and lung disease.12
It is suitable for elderly persons who may not be able to use either
a bicycle or treadmill and has physiologic validity in allowing the
subject to walk at his or her own pace. The distance walked was re-
corded by the investigator walking with the patient and pushing
a pedometer.
Analysis
A sample size of 45 per group was expected to allow detection of a 5
mmHg difference in mean gradient with 90% power. The mean and
standard deviation (SD) values were calculated for variables that
were normally distributed and the median and range for those that
were skewed. Clinical events were expressed as a proportion of
the whole population and the incidence of regurgitation was ex-
pressed as a proportion of those having echocardiograms. Compar-
isons were made between valve types using the unpaired t test or
nonparametric Mann–Whitney U test as appropriate, with analyses
both by intention to treat and actual valve implanted. There were no
material differences between the two analyses, so the analysis by ac-
tual valve implanted was reported. There were no missing data
points for those echocardiographic studies performed. The inci-
dence of regurgitation was compared by the Fisher exact test. Anal-
yses were performed by the Statistical Package for Social Sciences
version 11.5.1 for Windows (SPSS, Inc, Chicago, Ill).
Results
The patients were similar in terms of preoperative character-
istics (Table 1). Crossclamp time was similar, 74 (SD 25)
minutes for the Mosaic and 72 (SD 17) minutes for the Peri-
mount bioprostheses. Total bypass time was also similar, 95
(SD 31) minutes for the Mosaic and 95 (SD 30) for the Peri-
mount valves. The label sizes for the two valve designs were
similar and on average approximately 1 mm smaller than the
tissue annulus diameter determined by the independent sizer
(Table 2).
For peak and mean transvalve pressure difference, there
were small but statistically significant differences in favor
of the Perimount valve both postoperatively and at 1 year.
The effective orifice area was slightly larger in the Perimount
valve postoperatively, but there was no significant difference
(NS) at 1 year (Table 3). These differences were also apparent
in the valves when compared by label size (Table 4). Patient–
prosthesis mismatch occurred in 40 (82%) Mosaic compared
with 30 (64%) Perimount valves (NS). Severe mismatch1144 The Journal of Thoracic and Cardiovascular Surgery c Nooccurred in 22 (45%) Mosaic compared with 14 (30%) Peri-
mount valves (NS).
At 1 year there was trivial or mild regurgitation through
the valve in 8 Mosaic and 13 Perimount valves (NS) and triv-
ial or mild paraprosthetic regurgitation in 4 Mosaic and 2
Perimount valves (NS). One valve in each group had regur-
gitant jets in both a paraprosthetic position and through the
valve. Only one of the paraprosthetic jets was associated
with continuous sutures.
There were no differences in preoperative or postoperative
LV dimensions, LV mass index, fractional shortening, or LV
outflow velocity integrals between the Mosaic and Perimount
groups (Table 5). The ejection fraction was above 50% in 44
(88%) Mosaic and 38 (81%) Perimount valves and below
30% in 1 Mosaic and 2 Perimount valves.
There were no statistically significant differences in mor-
tality and clinical events between the two valve types. There
was 1 early death (within 30 days) in the Mosaic group and 1
TABLE 2. Comparison between tissue annulus diameter
and label size for the Mosaic and Perimount valves
Mosaic implanted Perimount implanted
Tissue
annulus
Mosaic
sizer
Perimount
sizer
Mosaic
sizer
Perimount
sizer
19 19.0 (0.0) 19.0 (0.0) 19.0 (0.0) 19.0 (0.0)
20 19.0 (0.0) 19.0 (0.0) — —
21 20.6 (0.8) 20.6 (0.8) 20.8 (0.6) 20.8 (0.6)
22 21.0 (0.0) 21.0 (0.0) 21.0 (0.0) 21.0 (0.0)
23 22.3 (1.0) 22.3 (1.0) 22.4 (1.0) 22.6 (1.2)
24 21.5 (1.0) 22.0 (1.2) 23.0 (1.6) 22.5 (1.0)
25 24.1 (1.1) 24.1 (1.1) 24.2 (1.1) 24.2 (1.1)
26 — — — —
27 26.0 (1.4) 26.0 (1.4) 26.0 (1.4) 26.0 (1.4)
28 — — 27.0 (0.0) 27 (0.0)
29 28.0 (1.4) 28.0 (1.4) 25.5 (1.0) 25.5 (1.0)
TABLE 3. Hemodynamic function postoperatively and at 1
year
Variable Mosaic Perimount P value
Postop
N 49 47
EOA (cm2) 1.28 6 0.46 1.47 6 0.45 .05
Peak DP (mm Hg) 28 6 13 19 6 9 ,.0001
Mean DP (mm Hg) 17 6 7 11 6 5 ,.0001
One year
N 40 37
EOA (cm2) 1.33 6 0.31 1.42 6 0.46 NS
Peak DP (mm Hg) 28 6 11 19 6 8 ,.0001
Mean DP (mm Hg) 15 6 6 11 6 4 ,.0001
EOA, Effective orifice area by the continuity equation; DP, pressure differ-
ence; NS, not significant.vember 2008
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days and 12 months) in the Mosaic group and 5 in the Peri-
mount group. There were 3 perioperative strokes in the Mo-
saic group and 2 in the Perimount group. There were 2 early
thromboembolic events in theMosaic group and 1 in the Peri-
mount group. There were 2 late thromboembolic events in the
Mosaic and 1 in the Perimount group. There was no endocar-
ditis or valve thrombosis.
Functional Measures
Six-minute walk distance for the Mosaic valve increased
from 255 m (SD 119 m) preoperatively to 366 m (SD 121
m) postoperatively (P , .0001). For the Perimount group,
the preoperative walk distance of 223 m (SD 129 m) in-
creased to 334 m (SD 104 m) (P 5 .002). There were 51
(SD 65%) patients in NYHA class I at 1 year, 27 Mosaic
and 24 Perimount. There were 25 (32%) in class II, 12 Mo-
saic and 13 Perimount. Only 1Mosaic and 2 Perimount valve
TABLE 4. Hemodynamic function (mean 6 standard
deviation) postoperatively by label size
Label size Mosaic Perimount P value
19 n 5 5 n 5 4
EOA (cm2) 0.93 6 0.34 1.10 6 0.29 NS
EOAi (cm2) 0.58 6 0.24 0.67 6 0.17 NS
Peak DP (mm Hg) 42 6 15 31 6 8 NS
Mean DP (mm Hg) 23 6 8 16 6 4 NS
21 n 5 19 n 5 19
EOA (cm2) 1.13 6 0.37 1.27 6 0.25 NS
EOAi (cm2) 0.63 6 0.26 0.72 6 0.16 NS
Peak DP (mm Hg) 34 6 11 22 6 7 .001
Mean DP (mm Hg) 19 6 7 13 6 5 .003
23 n 5 17 n 5 15
EOA (cm2) 1.43 6 0.41 1.71 6 0.42 NS
EOAi (cm2) 0.80 6 0.24 0.91 6 0.23 NS
Peak DP (mm Hg) 24 6 10 14 6 6 .003
Mean DP (mm Hg) 13 6 6 8 6 4 .005
25 n 5 7 n 5 6
EOA (cm2) 1.29 6 0.60 1.43 6 0.55 NS
EOAi (cm2) 0.79 6 0.23 0.77 6 0.28 NS
Peak DP (mm Hg) 19 6 6 18 6 10 NS
Mean DP (mm Hg) 13 6 7 10 6 6 NS
27 n 5 1 n 5 3
EOA (cm2) 1.60 2.13 6 0.45 —
EOAi (cm2) 0.76 1.1 6 0.2 —
Peak DP (mm Hg) 15 13 6 7 —
Mean DP (mm Hg) 9 7 6 3 —
29 1
EOA (cm2) 2.3 —
EOAi (cm2) 1.25 —
Peak DP (mm Hg) 13 —
Mean DP (mm Hg) 7.2 —
EOA, Effective orifice area by the continuity equation; EOAi, indexed effec-
tive orifice area; DP, pressure difference; NS, not significant.The Journal of Thorarecipients were in NYHA class III, and no patients were in
class IV. There were no differences between the valve types
either before or after surgery in terms of 6-minute walk dis-
tance or NYHA class.
There were improvements in both anxiety and depression
scores after surgery for each valve design, but no difference
between the valve designs (Table 6a). Similarly, both mental
and physical composite scores on the SF-36 questionnaire
improved after surgery but with no difference between the
valve types (Table 6b). The change in physical score was
greater than for mental score.
Discussion
This randomized study suggests better hemodynamic func-
tion in a pericardial compared with a porcine stented valve.
The peak and mean pressure differences were statistically
lower with the pericardial valve (P , .0001) both postoper-
atively and at 1 year although the clinical difference was rel-
atively small, 6 mm Hg in the mean and 9 mm Hg in the peak
pressure difference. Pressure difference is dependent on flow,
but there was also a non–statistically significant trend to
a larger effective orifice area in the pericardial valve both
postoperatively (1.47 vs 1.28 cm2; P 5 .05) and at 1 year
(1.42 vs 1.33 cm2) using the relatively flow-independent con-
tinuity equation. The incidence of patient–prosthesis mis-
match was lower, 30 (64%) for the pericardial Perimount
compared with 40 (82%) with the porcine Mosaic valve, al-
though the difference was not statistically significant.
There were no discrepancies in the hemodynamic results
in comparison with previously published studies of the
Mosaic or Perimount valves.13-23 In general, nonrandomized
studies tend to show better hemodynamic function for peri-
cardial compared with porcine valves. Peak pressure differ-
ence for pericardial valves of label size 23 mm is around
15 mm Hg1 compared with a range of 18 to 32 mm Hg for
porcine valves of similar label size.2,3 However, variations
in sizing convention mean that valves of different design
with the same label size may fit different patient tissue annu-
lus diameters, which necessitates randomization of two com-
parator valves. A study5 with a design similar to ours found
that the mean pressure difference at rest was higher for the
Mosaic valve at 14.6 mm Hg than for the Perimount valve
at 11.4 mm Hg (P , .05). However, the mean effective ori-
fice area was similar, 1.49 cm2 for the Mosaic and 1.56 cm2
for the Perimount valve. Seitelberger and associates6 also
found that the Perimount was hemodynamically superior to
the Mosaic bioprosthesis when compared by label size. How-
ever, hemodynamic function was similar when the two valve
designs were compared according to patient tissue annulus.
This result is different from ours and from the previous study
by Eichinger and colleagues5 and may be explained by differ-
ences in sizing. The Mosaic valve is a true supra-annular de-
sign, whereas the Perimount pericardial bioprosthesis has an
intra-annular stent design with a supra-annular cuff. Thiscic and Cardiovascular Surgery c Volume 136, Number 5 1145
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Mosaic Perimount 95% CI P value
LVDD (cm) Pre 5.1 6 0.86 46 4.9 6 1.1 46 22.7, 0.54 NS
LVDD (cm) Post 4.6 6 0.9 49 4.7 6 0.9 46 20.52, 0.17 NS
LVDD (cm) 12 mo 4.5 6 0.8 39 4.6 6 0.9 36 20.52, 0.36 NS
LVMI Pre 233 6 123 41 211 6 77 44 223, 66 NS
LVMI g/m2 Post 176 6 63 46 183 6 59 42 233, 19 NS
LVMI g/m2 12 mo 152 6 50 38 160 6 62 36 234, 18 NS
FS (%) Pre 35 6 9 42 32 6 11 44 22.1, 6.7 NS
FS (%) Post 31 6 10 44 32 6 10 38 25.6, 3.1 NS
FS (%) 12 mo 36 6 8 36 34 610 34 22.2, 6.6 NS
LVOT VTI Pre 21 6 5 51 20 6 5 48 21, 3 NS
LVOT VTI Post 17 6 4 50 17 6 4 47 21, 2 NS
LVOT VTI 12 mo 22 6 5 40 20 6 5 37 20.03, 4.3 NS
CI, Confidence interval; LVDD, left ventricular diastolic diameter; LVMI, left ventricular mass index; FS, fractional shortening; LVOT, left ventricular outflow
tract; VTI, velocity time integral; NS, not significant.would suggest that a larger Mosaic valve might be implanted.
However, in our study the label sizes were similar. By con-
trast, in the study by Seitelberger and associates,6 the Peri-
mount valves tended to be smaller inasmuch as there were
10 Perimount but no Mosaic valves at label size 19. It is pos-
sible that there was an unintentional bias in favor of the Mo-
saic in the study of Seitelberger and coworkers.6 The body
surface area of the patients was not given, but there were 8
patients with a 19-mm tissue annulus diameter as measured
by an independent sizer and all of these were implanted
with a Perimount valve. On the other hand, our study could
have been biased toward the Perimount valve if the label
size of the Mosaic valve was limited not by the tissue annulus
but by the size of the aortic root, as occurs with other supra-
annular valves.24
The overriding concern in research in the past has been the
objective assessment of hemodynamic function and clinical
event rates including mortality. What also matters to a patient
is exercise ability and quality of life. The minor hemody-
namic difference did not translate to any difference in exer-
cise ability, although after surgery both groups had large
and clinically significant improvements compared with pre-
operative levels. The 6-minute walk is a simple physiologic
TABLE 6a. Hospital and anxiety questionnaire (mean 6
standard deviation)
Mosaic N Perimount N P value
Anxiety (pre) 7.2 6 3.7 46 7.6 6 4.4 47 NS
Anxiety (12 mo) 5.0 6 3.0 40 4.2 6 3.7 38 NS
P value .001 ,.0001
Depression (pre) 5.9 6 3.5 46 6.1 6 4.1 47 NS
Depression (12 mo) 4.4 6 2.8 40 4.4 6 3.7 37 NS
P value .003 .032
NS, Not significant.1146 The Journal of Thoracic and Cardiovascular Surgery c Novmeasure of exercise capacity that can be performed by
most patients. It is likely to be more representative than the
NYHA class. Similarly, both groups showed large improve-
ment in anxiety and depression scores using the Hospital
Anxiety and Depression scale and in mental and physical
scores using the SF-36 questionnaire. The improvement
was predominantly in physical score (12.8 for the Perimount
valve and 10.2 for the Mosaic valve) rather than the mental
composite score (4.7 for the Perimount valve and 3.5 for
the Mosaic valve). Little previously published work exists,
but our results are consistent with Ware and Kosinski’s25 es-
timation of mental and physical composite scores from
a study of 94 patients having valve surgery.26 They showed
that an improvement in score at 6 months after surgery oc-
curred mainly for the physical score (7.6 points) rather than
the mental score (3.2 points). However, this may be because
the mental score was less reduced before surgery than the
physical score. In our study, both scores were similar after
surgery to the expected normal range, which for a US popu-
lation aged older than 75 years is 37.9 (SD 11.2) for physical
and 50.4 (SD 11.7) for mental score.9 We also showed signif-
icant improvements in both the depression and anxiety scores
TABLE 6b. SF-36 questionnaire (mean 6 standard
deviation)
Mosaic N Perimount N P value
PCS (pre) 28.1 6 11.8 46 26.0 6 9.9 46 NS
PCS (12 mo) 38.3 6 11.7 38 38.8 6 12.03 38 NS
P value <.0001 <.0001
MCS (pre) 47.6 6 10.8 46 45.2 6 11.8 47 NS
MCS (12 mo) 51.1 6 8.6 38 49.9 6 12.6 38 NS
P value .005 .009
SF-36, Short Form-36; PCS, Physical composite score;MCS,mental compos-
ite score; NS, not significant.ember 2008
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none of these functional measures was there any difference
between the two valve types.
Clinical Implications
There is general agreement that patient–prosthesis mismatch
has adverse clinical effects, particularly in patients with im-
paired LV function.27-29 Despite this, we found no difference
in exercise capacity or regression of LV hypertrophy al-
though our patients were observed only to 1 year. It is also
possible that valves with a larger effective orifice area will al-
low patients to avoid symptoms for longer as progressive ste-
nosis develops as a result of primary valve failure. This could
reduce the risk of cardiac events and reoperation in the long
term.
Limitations
This study reports information to only 1 year, and it is possi-
ble that late event rates or durability may differ. Furthermore,
the study was primarily concerned with hemodynamic func-
tion and was not powered to detect small differences in event
rates. There was a trend in effective orifice area in favor of the
Perimount valve, which might have been statistically signif-
icant with a larger population size. It is also possible that the
hemodynamic differences might have been greater had we
been able to use the Carpentier-Edwards Perimount Magna
valve (Edwards Lifesciences, Irvine, Calif), which is a wholly
supra-annular version of the Perimount design. However,
a comparison of the Perimount Magna with the Mosaic30
found a mean pressure difference of 10.2 versus 17.1 mm
Hg, which is similar to our results (11 vs 17 mm Hg). Al-
though all surviving patients were studied immediately after
surgery, 22 subjects could not have echocardiography at 1
year. Despite this, the hemodynamic results were similar at
both time points.
Conclusion
In this randomized comparison of the Mosaic and Perimount
valves, there were minor differences in hemodynamic func-
tion in favor of the Perimount valve. Both valves were asso-
ciated with similar and significant improvements in quality of
life, exercise ability, and regression of LV mass.
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